JM 2929
Latest Information Update: 12 Dec 1997
At a glance
- Originator AnorMED
- Class Antineoplastics
- Mechanism of Action Photosensitisers; Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Dec 1997 Discontinued-Preclinical for Cancer in USA (Unknown route)